Beata Ledwon, Andrzej Miskiewicz, Renata Górska

The influence of periodontitis treatment on falls reduction in the course of Parkinson’s disease

Streszczenie
Obawa przed upadkiem stanowi istotny czynnik obniżający jakość życia pacjentów ze zdiagnozowaną chorobą Parkinsona. Ze względu na ograniczoną sprawność psychomotoryczną chorego wystąpienie upadku wiąże się z możliwością odniesienia urazu. Do chwili obecnej nie opracowano metod wpływających na zmniejszenie liczby upadków w przebiegu choroby Parkinsona.
Grupa badana. Do badania zakwalifikowano 61 osób ze zdiagnozowaną i aktywnie leczoną chorobą Parkinsona w wieku 49-85 lat. Badanie periodontologiczne przeprowadzono w oparciu o parametry diagnostyczne zapalenia przyzębia wg Amerykańskiej Akademii Periodotologii (AAP), natomiast aktywność zapalenia przyzębia oceniano w skali wg S. Offenbachera.
Wyniki. W grupie pacjentów w wieku 49-74 lat ze zdiagnozowaną chorobą Parkinsona i zapaleniem przyzębia uzyskano znaczną redukcję liczby upadków w trakcie leczenia periodontologicznego oraz po jego zakończeniu. Liczba upadków zmalała odpowiednio: o 77% po 3 miesiącach leczenia i o 71% po 9 miesiącach. Ponadto u wszystkich pacjentów wykazano korelację dodatnią pomiędzy redukcją głębokości kieszonek przyzębnych a zmniejszeniem liczby upadków.
Wniosek. Objęcie intensywnym leczeniem periodontologicznym pacjentów w przebiegu choroby Parkinsona zmniejsza liczbę upadków.

Abstract
A fear of falling is constitutionally enrolled in everyday activity in patients with Parkinson's disease. It affects significantly the quality of life due to a possible risk of major injuries suffered from a fall. Up-to-date there has been no established way to reduce the number of occuring falls.
Aim of the study. The aim of the study was an evaluation of periodontitis treatment in patients diagnosed with Parkinson's diseaseand to compare tothe general number of falls in the course of the condition. The study group consisted of 61 people at the age of 49-85 years, who suffered from Parkinson’s disease. The patients were treated for periodontitis and Parkinson’s disease.
Results. In the group of patinets in the age 49-74 it was observed a significant reduction of falls after 3 months and 9 months of periodontal treatment: respectively 77% and 71%. Moreover in every subject diagnosed with periodontitis we observed a positive correlation between reduction of probing depth (PD) and number of occuring falls.
Conclusion. The study has demonstrated the effect of treatment of periodontitis on the reduction of falls in patients with Parkinson’s disease.

Hasła indeksowe: choroba Parkinsona, zapalenie przyzębia, choroby neurodegeneracyjne

Key words: Parkinson disease, periodontitis, neurodegenerative conditions

PIŚMIENNICTWO
1. Bower J.H., Maraganore D.M., McDonnell S.K., Rocca W.A.: Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology, 1999, 52, 1214-1220.
2. Clerici I., Ferrazzoli D., Maestri R. i wsp.:  Rehabilitation in progressive\supranuclear palsy: effectiveness of two multidisciplinary treatments. PLOS ONE, 2017, 12, e0170927.
3. Voss T.S., Elm J.J., Wielinski C.L. i wsp.: Fall frequency and risk assessment in early Parkinson’s disease. Parkinsonism Rel. Disord., 2012, 18, 837-841.
4. Ryu S.H., Jung H.Y., Lee K.J. i wsp.: Incidence and course of depression in patients with Alzheimer’s disease. Psychiatry Invest., 2017, 14, 271-280.
5. Deane K.H., Flaherty H., Daley D.J. i wsp.: Priority setting partnership to identify the top 10 research priorities for the management of Parkinson’s disease. BMJ open, 2014, 4, e006434.
6. Lindholm B., Hagell P., Hansson O., Nilsson M.H.: Prediction of falls and/or near falls in people with mild Parkinson’s disease. PLOS ONE, 2015, 10, e0117018.
7. Latt M.D., Lord S.R., Morris J.G., Fung V.S.: Clinical and physiological assessments for elucidating falls risk in Parkinson’s disease. Mov. Disorders, 2009, 24, 1280-1289.
8. Pickering R.M., Grimbergen Y.A., Rigney U. i wsp.:A meta-analysis of six prospective studies of falling in Parkinson’s disease. Mov. Disord., 2007, 22,1892-1900.
9. Pierce S., Coetzee G.A.: Parkinson’s disease-associated genetic variation is linked to quantitative expression of inflammatory genes. PLOS ONE, 2017, 12, e0175882.
10. Lee B.D., Shin J.H., VanKampen J.i wsp.: Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson’s disease. Nature Med., 2010, 16, 998-1000.
11. Genco R.J., Borgnakke W.S.: Risk factors for periodontal disease. Periodontol. 2000 , 2013, 62, 59-94.
12. Hanaoka A., Kashihara K.: Increased frequencies of caries, periodontal disease and tooth loss in patients with Parkinson’s disease. J. Clin. Neurosci., 2009,16, 1279-1282.
13. Chapple I.L., Genco R., working group 2 of the joint EFPAAP w.:Diabetes and periodontal diseases: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. J. Periodontol., 2013, 84, S106-112.
14. Herrera A.J., Tomas-Camardiel M., Venero J.L. i wsp.: Inflammatory process as a determinant factor for the degeneration of substantia nigra dopaminergic neurons. J. Neural Transm., 2005, 112, 111.
15. Herrera A.J., Castano A., Venero J.L. i wsp.: The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol. Dis., 2000, 7, 429-447.
16. Perry V.H.: Contribution of systemic inflammation to chronic neurodegeneration. Acta Neuropathol., 2010, 120, 277-286.
17. Perry V.H., Cunningham C., Holmes C.: Systemic infections and inflammation affect chronic neurodegeneration. Nature Rev. Immunol., 2007, 7, 161-167.
18. Perry V.H., Holmes C.: Microglial priming in neurodegenerative disease. Nature Rev. Neurol., 2014, 10, 217-224.
19. Perry V.H., Newman T.A., Cunningham C.: The impact of systemic infection on the progression of neurodegenerative disease. Nature Rev. Neurosci., 2003, 4, 103-112.
20. Perry V.H., Nicoll J.A., Holmes C.: Microglia in neurodegenerative disease. Nature Rev. Neurol., 2010, 6, 193-201.
21. Kamer A.R., Pirraglia E., Tsui W. i wsp.: Periodontal disease associates with higher brain amyloid load in normal elderly. Neurobiol. Aging, 2015, 36, 627-633.
22. Gao X., Chen H., Schwarzschild M.A., Ascherio A.: Use of ibuprofen and risk of Parkinson disease. Neurology, 2011, 76, 863-869.
23. Koller W.C., Glatt S., Vetere-Overfield B., Hassanein R.: Falls and Parkinson’s disease. Clin. Neuropharmacol., 1989, 12, 98-105.
24. Kannus P., Parkkari J., Niemi S. i wsp.: Prevention of hip fracture in elderly people with use of a hip protector. New Engl. J. Med., 2000, 343, 1506-1513.
25. Wood B.H., Bilclough J.A., Bowron A., Walker R.W.: Incidence and prediction of falls in Parkinson’s disease: a prospective multidisciplinary study. J. Neurol. Neurosurg., Psychiatry, 2002, 72,721-725.
26. Ashburn A., Fazakarley L., Ballinger C. i wsp.: A randomised controlled trial of a home based exercise programme to reduce the risk of falling among people with Parkinson’s disease. J. Neurol. Neurosurg.,
Psychiatry, 2007, 78, 678-684
27. von Renteln-Kruse W., Krause T.: Fall events in geriatric hospital in-patients . Results of prospective recording over a 3 year period. Z. Gerontol. Geriatr., 2004, 37, 1, 9-14.
28. Boereboom F.T., Raymakers Ja, Duurusma S.A.: Mortality and causes of death after hip fractures in The Netherlands. Neth. J. Med., 1992, 41, 1-2, 4-10.
29. Ashburn A., Stack E., Pickering R.M., Ward C.D.: A community-dwelling sample of people with Parkinson’s disease: characteristics of fallers and non-fallers. Age Ageing, 2001, 30, 47-52.